297135-64-9

Upstream product

• 297135-61-6 (6R,7S,10R)-4-[(2S,4S)-5-[2-((2S,6R)-6-Benzyloxymethyl-4,4-dimethoxy-tetrahydro-pyran-2-ylmethyl)-[1,3]dithian-2-yl]-4-(tert-butyl-dimethyl-silanyloxy)-2-hydroxy-5-methyl-hexyl]-7-isopropyl-10-methyl-1,5-dioxa-spiro[5.5]undec-3-en-2-one 
• 2916-68-9 2-(Trimethylsilyl)ethanol 
• 297135-63-8 (5S,7S)-8-[2-((2S,6R)-6-Benzyloxymethyl-4,4-dimethoxy-tetrahydro-pyran-2-ylmethyl)-[1,3]dithian-2-yl]-7-(tert-butyl-dimethyl-silanyloxy)-5-hydroxy-8-methyl-3-oxo-nonanoic acid 2-trimethylsilanyl-ethyl ester 

Downstream Products

• 297135-65-0 4-[6-(6-benzyloxymethyl-4,4-dimethoxy-tetrahydro-pyran-2-ylmethyl)-4-(tert-butyl-dimethyl-silanyloxy)-6-methoxy-5,5-dimethyl-tetrahydro-pyran-2-yl]-3-(tert-butyl-dimethyl-silanyloxy)-butyric acid 2-trimethylsilanyl-ethyl ester 

Relevant academic research and scientific papers

Total synthesis of bryostatin 3

A convergent synthetic strategy has been used to accomplish the first total synthesis of the title compound 1, a γ-lactone- containing member of the antineoplastic marine macrolide family. The C1-C16 and C17-C27 fragments were combined by the Julia- Lythgoe olefination and the Yamaguchi macrolactonization. This was followed by the stereoselective introduction of a methoxycarbonyl-methylene group, and final hydrolysis of the acetal provided access to the target molecule 1.